T
TSCAN THERAPEUTICS INC
NASDAQ: TCRX (TScan Therapeutics, Inc.)
最近更新时间: 6小时之前0.381
-0.29 (-42.80%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | TScan Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
0.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.23% |
| 机构持股比例 | 88.08% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 2,784,792 |
| Deer Management Co. Llc | 30 Jun 2026 | 1,245,504 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,049,806 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合